eteplirsen (Exondys 51) Report issue

Biologics Nucleic acid Orphan Drug FDA Approved FDA Fast Track FDA Accelerated Approval FDA Priority Review FDA

Active Ingredient History

  • Now
Eteplirsen is a medication to treat, but not cure, some types of Duchenne muscular dystrophy (DMD), caused by a specific mutation. Eteplirsen only targets specific mutations and can be used to treat about 14% of DMD cases. Eteplirsen is a form of antisense therapy.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$1222.1100 - $7959.8000
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

avi 4658 | avi-4658 | eteplirsen | exondys 51 | (p-deoxy-p-(dimethylamino)](2',3'-dideoxy-2',3'-imino-2',3'-seco)(2'a→5')(c-m5u-c-c-a-a-c-a-m5u-c-a-a-g-g-a-a-g-a-m5u-g-g-c-a-m5u-m5u-m5u-c-m5u-a-g),5'-(p-(4-((2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)carbonyl)-1-piperazinyl)-n,n-dimethylphosphonamidate) rna


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue